Source comparison
Tesamorelin Body Composition: Treatment Comparison
Tesamorelin 2mg daily 15–20% reduction 3–5% reduction Stable to +1.5kg GHRH receptor agonist → pulsatile GH → selective VAT lipolysis Gold standard for visceral fat targeting. Minimal effect on appearance-based fat loss Growth Hormone 2–4 IU daily 12–18% reduc
This comparison does not assign a generated winner or score.
- Tesamorelin 2mg daily
- 15–20% reduction
- 3–5% reduction
- Stable to +1.5kg
- GHRH receptor agonist → pulsatile GH → selective VAT lipolysis
- Gold standard for visceral fat targeting. Minimal effect on appearance-based fat loss
- Growth Hormone 2–4 IU daily
- 12–18% reduction
- 8–12% reduction
- +2–4kg
- Direct GH receptor activation → generalized lipolysis + anabolism
- Broader body composition effects but higher cost and side effect burden
- CJC-1295 + Ipamorelin
- 5–8% reduction
- +1–2kg
- GHRH + ghrelin mimetic → moderate GH pulses
- Moderate efficacy at lower cost. Less selective than tesamorelin
- Semaglutide 2.4mg weekly
- −2–3kg lean mass
- GLP-1 agonist → appetite suppression + weight loss
- Effective for total fat loss but reduces lean mass. Opposite selectivity profile